Prime Medicine, Inc. Income Statement
PRME / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Prime Medicine, Inc. reported $5M in revenue and $201M in net loss for FY2025. Revenue has declined at a 2.3% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $0 | $0 | $5.2M |
| SG&A Expense | $52.3M | $50.2M | $43.4M | $29.8M | $13.9M | $3.2M |
| R&D Expense | $160.6M | $155.3M | $147.9M | $86.7M | $70.5M | $3.0M |
| Operating Income | -$208.3M | -$202.5M | -$204.8M | -$116.5M | -$84.5M | -$932.0K |
| Income Tax | $0 | $0 | -$279.0K | -$948.0K | -$486.0K | $1.9M |
| Net Income | -$201.1M | -$195.9M | -$198.1M | -$121.8M | -$165.4M | -$3.4M |
| EPS (Basic) | -$1.35 | -$1.65 | -$2.18 | -$1.91 | -$14.19 | -$1.91 |
| EPS (Diluted) | -$1.35 | -$1.65 | -$2.18 | -$1.91 | -$14.19 | -$1.91 |
| Shares Outstanding | 180.5M | 131.2M | 91.0M | 32.4M | 13.0M | 2.6M |
| Operating Margin | -4498.1% | -6787.4% | - | - | - | -17.9% |
| Profit Margin | -4342.4% | -6566.6% | - | - | - | -65.5% |